Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial

BACKGROUND: Axial involvement constitutes a specific domain of psoriatic arthritis (PsA). Interleukin (IL)-23 inhibitors have demonstrated improvement in axial PsA (axPsA) symptoms, but have not shown efficacy in treating ankylosing spondylitis (AS), suggesting differences in axPsA processes and tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Gladman, Dafna D., Mease, Philip J., Bird, Paul, Soriano, Enrique R., Chakravarty, Soumya D., Shawi, May, Xu, Stephen, Quinn, Sean T., Gong, Cinty, Leibowitz, Evan, Poddubnyy, Denis, Tam, Lai-Shan, Helliwell, Philip S., Kavanaugh, Arthur, Deodhar, Atul, Østergaard, Mikkel, Baraliakos, Xenofon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444112/
https://www.ncbi.nlm.nih.gov/pubmed/36064592
http://dx.doi.org/10.1186/s13063-022-06589-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444112/
https://www.ncbi.nlm.nih.gov/pubmed/36064592
http://dx.doi.org/10.1186/s13063-022-06589-y

Ejemplares similares